FIRST-IN-CLASS TRPM3 ANTAGONIST FOR NEUROPATHIC PAIN
BHV-2100 is Biohaven’s first-in-class molecule directed against TRPM3, a novel druggable target in the transient receptor potential (TRP) cation channel family.
TRPM3 is a Novel Druggable Target in the TRP Channel Family
![Biohaven TRPM3 is a novel druggable target in the TRP channel family](https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-TRPM3-is-a-novel-druggable-target-in-the-TRP-channel-family-1.png)